Stockreport

Sierra Oncology Reports Decreased Transfusion Requirements for Patients Treated with Momelotinib Directly Compared to Ruxolitinib at ASH Annual Meeting

Sierra Oncology, Inc.  (SRRA) 
Last sierra oncology, inc. earnings: 3/3 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: investor.sierraoncology.com
PDF - New analyses of Phase 3 data highlighting momelotinib's meaningful anemia benefits in myelofibrosis presented in a poster at the 61st American Society of Hematology An [Read more]